Fdocuments - in Inventory Management in Johnson Johnson
Fdocuments - in Inventory Management in Johnson Johnson
A PROJECT REPORT
ON
Roll No.9929
ACKNOWLEDGEMENT
will be always need for improvement. Apart from this, I hope this
Contents
PART- I
*Introduction of Company
* Company Profile
* History
* Board of Directors
* Awards
* Products
* Research Methodology
PART- II
* Data Collection
* Financial Statements
* Conclusions
* Bibliography
OB J ECTIVE OF THE STUDY
C o m p a n y Pr o f i l e
Johnson & Johnson and its subsidiaries have approximately 115,500
employees worldwide engaged in the research and development,
manufacture and sale of a broad range of products in the health care field.
Johnson &Johnson is a holding company, which has more than 250
operating companies conducting business in virtually all countries of the
world. Johnson & Johnson‘s primary focus has been on products related to
human health and wellbeing.
Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Company‘s structure is based on the principle of decentralized
management. The Executive Committee of Johnson & Johnson is the
principal management group responsible for the operations and allocation
of the resources of the Company. This Committee oversees and coordinates
the activities of the Consumer, Pharmaceutical and Medical Devices and
Diagnostics business segments. Each subsidiary within the business
segments is, with some exceptions, managed by citizens of the country
where it is located. . Johnson & Johnson is known for its corporate
reputation, consistently ranking at the top of Interactive National Corporate
Reputation Survey ranking as the world's most respected company by
Barron'sMagazine, and was the first corporation awarded the Benjamin
Franklin Award for Public Diplomacy by the U.S. State Department for its
funding of international education programs. Johnson & Johnson is known
for its corporate reputation, consistently ranking at the top of Interactive
National Corporate Reputation Survey ranking as the world's most
respected company by Barron'sMagazine, and was the first corporation
awarded the Benjamin Franklin Award for Public Diplomacy by the U.S.
State Department for its funding of international education programs
Segments of Business
Johnson & Johnson ‘s operating companies are organized into three business
segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics.
C o n s u m e r
The Consumer segment includes a broad range of products used in the baby
care, skin care, oral care, wound care and women‘s health care fields, as
well as nutritional and over-the-counter pharmaceutical products, and
wellness and prevention platforms. The Baby Care franchise includes the
JOHNSON‘S Baby line of products. Major brands in the Skin Care franchise
include the AVEENO; CLEAN & CLEAR; JOHNSON’S Adult;
NEUTROGENA; RoC; LUBRIDERM; Dabao; and Vendôme product lines.
The Oral Care franchise includes the LISTERINE and REACH oral care lines
of products. The Wound Care franchise includes BAND-AID brand adhesive
bandages and PURELL instant hand sanitizer products. Major brands in the
Women‘s Health franchise are the CAREFREE Pantiliners; STAYFREE
sanitary protection products; and Vania Expansion products. The nutritional
and over-the-counter lines include SPLENDA , No Calorie Sweetener ; the
broad family of TYLENOL acetaminophen products; SUDAFED cold, flu
and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen
products; and PEPCID AC Acid Controller from Johnson & Johnson Merck•
Pharmaceutical
The Pharmaceutical segment includes products in the following therapeutic
areas: anti-infective, antipsychotic, cardiovascular, contraceptive,
dermatology, gastrointestinal, hematology, immunology, neurology,
oncology, pain management, urology and virology. These products are
distributed directly to retailers, wholesalers and health care professionals
for prescription use. Key products in the Pharmaceutical segment include:
REMICADE (infliximab), a biologic approved for the treatment of a number
of immune mediated inflammatory diseases; PROCRIT (Epoetin Alfa, sold
outside the U.S. as EPREX), a biotechnology-derived product that
stimulates red blood cell production;
LEVAQUIN (levofloxacin) in the anti-infective field; RISPERDAL CONSTA
(risperidone), a long-acting inject able for the treatment of schizophrenia;
M e d i c a l D ev i c e s an d D i a g n o s t i c s
The Medical Devices and Diagnostics segment includes a broad range of
products distributed to wholesalers, hospitals and retailers, used principally
in the professional fields by physicians, nurses, therapists, hospitals,
diagnostic laboratories and clinics. These products include Cordis’
circulatory disease management products;DePuy‘s orthopaedic joint
reconstruction, spinal care and sports medicine products; Ethicon‘s
surgical care, aesthetics and women‘s health products; Ethicon Endo-
Surgery’s minimally invasive surgical products; LifeScan‘sblood glucose
monitoring and insulin delivery products; Ortho-Clinical Diagnostics‘
professional diagnostic products; and Vistakon‘s disposable contact lenses.
Distribution to these health care professional markets is done both directly
and through surgical supply and other dealers.
Geographic Areas
The international business of Johnson & Johnson is conducted by
subsidiaries located in 59 countries outside the United States, which are
selling products in virtually all countries throughout the world. The products
made and sold in the international business include many of those
described above under ―— Segments of Business — Consumer,‖―—
Pharmaceutical‖ and ―— Medical Devices and Diagnostics.‖ However, the
principal markets, products and methods of distribution in the international
business vary with the country and the culture. The products sold in
international business include not only those developed in the United
States, but also those developed by subsidiaries abroad.
Investments and activities in some countries outside the United States are
subject to higher risks than comparable U.S. activities because the
investment and commercial climate is influenced by restrictive economic
policies and political uncertainties.
Raw Materials
Raw materials essential to Johnson & Johnson‘s operating companies‘
businesses are generally readily available from multiple sources.
Environment
Johnson & Johnson‘s operating companies are subject to a variety of U.S.
and international environmental protection measures. Johnson & Johnson
believes that its operations comply in all material respects with applicable
environmental laws and regulations. Johnson & Johnson‘s compliance with
these requirements did not during the past year, and is not expected to,
have a material effect upon its capital expenditures, cash flows, earnings or
competitive position.
Regulation
Most of Johnson & Johnson‘s businesses are subject to varying degrees of
governmental regulation in the countries in which operations are conducted,
and the general trend is toward increasingly stringent regulation. In the
United States, the drug, device, diagnostics and cosmetic industries have
long been subject to regulation by various federal and state agencies,
primarily as to product safety, efficacy, manufacturing, advertising, labeling
and safety reporting. The exercise of broad regulatory powers by the FDA
continues to result in increases in the amounts of testing and
documentation required for FDA clearance of new drugs and devices and a
corresponding increase in the expense of product introduction. Similar
trends are also evident in major markets outside of the United States. The
costs of human health care have been and continue to be a subject of
study, investigation and regulation by governmental agencies and
legislative bodies around the world. In the United States, attention has been
focused on drug prices and profits and programs that encourage doctors to
write prescriptions for particular drugs or recommend, use or purchase
particular medical devices. Payers have become a more potent force in the
market place and increased attention is being paid to drug and medical
device pricing, appropriate drug and medical device utilization and the
quality and costs of health care. The regulatory agencies under whose
purview Johnson & Johnson‘s operating companies operate have
administrative powers that may subject those companies to such actions as
product withdrawals, recalls, seizure of products and other civil and criminal
sanctions. In some cases, Johnson & Johnson‘s operating companies may
deem it advisable to initiate product recalls. In addition, business practices
in the health care industry have come under increased scrutiny, particularly
in the United States, by government agencies and state attorneys general,
and resulting investigations and prosecutions carry the risk of significant
civil and criminal penalties.
PROPERTIES
Johnson & Johnson and its subsidiaries operate 143 manufacturing facilities
occupying approximately 21.4 million square feet of floor space. The
manufacturing facilities are used by the industry segments of Johnson &
Johnson‘s business approximately as follows:
Available Information
Square Feet
(in Segment thousands)
Consumer 6,825
Pharmaceutical 6,369
Medical Devices and Diagnostics 8,251
Worldwide Total 21,445
Within the United States, 7 facilities are used by the Consumer segment, 12
by the Pharmaceutical segment and 37 by the Medical Devices and
Diagnostics segment. Johnson & Johnson‘s manufacturing operations
outside the United States are often conducted in facilities that serve more
than one business segment.
Listed below are the executive officers of Johnson & Johnson as of February
8, 2010, each of whom, unless otherwise indicated below, has been an
employee of the Company or its affiliates and held the position indicated
during the past five years. There are no family relationships between any of
the executive officers, and there is no arrangement or understanding
between any executive officer and any other person pursuant to which the
executive officer was selected. At the annual meeting of the Board of
Directors, the executive officers are elected by the Board to hold office for
one year and until their respective successors are elected and qualified, or
until earlier resignation or removal.
Information with regard to the directors of the Company, including those of
the following executive officers who are directors, is incorporated herein by
reference to the material captioned ―Election of Directors‖ in the Proxy
Statement.
Russell C. Deyo
Member, Executive Committee; Vice President, Human
Resources and General Counsel (b)
Colleen A. Goggins
Alex Gorsky
Member, Executive Committee; Worldwide Chairman, Medical
Devices and Diagnostics Group (d)
Sherilyn S. McCoy
Member, Executive Committee; Worldwide Chairman,
Pharmaceuticals Group (e)
William C. Weldon
Chairman, Board of Directors; Chairman, Executive
Committee; Chief Executive Officer
History
RobertWoodJohnson, inspired by a speech by antisepsis advocate
JosephLister, joined brothers JamesWoodJohnson and EdwardMead
Johnson t o create a line of ready-to-use surgicaldressings i n 1885. The
company produced its first products in 1886 and incorporated i n 1887.
Since the 1900s, the company has pursued steady diversification. It
added consumer products in the 1920s and created a separate division for
surgical products in 1941 which became Ethicon. It expanded into
pharmaceuticals with the purchase of McNeilLaboratories, Inc., Cilag , and
JanssenPharmaceutical , and into women's sanitary products and toiletries
in the 1970s and 1980s. In recent years, Johnson & Johnson has expanded
into such diverse areas as biopharmaceuticals, orthopedic devices, and
Internet publishing. Recently, Johnson & Johnson has purchased Pfizer's
Consumer Healthcare department. The transition from Pfizer to Johnson and
Johnson was completed December 18, 2006.
Johnson & Johnson has been consistently named one of the 100 Best
Companies for Working Mothers by Working Mother.
A b o u t E t h i c o n (B r an d N am e)
Our company was founded 80 years ago on the pillars of research,
vision, innovation, and a commitment to improving the quality of patient s’
lives. The first group of Ethicon scientists and researchers, who thought
about healing in a new way - and in doing so, pioneered our sutures to
enhance the work of surgeons and the lives of patients - recognized the
opportunity for limitless innovation.
Almost a century later, Ethicon produces much more than sutures. We have
continuously introduced innovations in all areas where we focus our
expertise including: wound closure; general surgery; biosurgery; women ’s
health, and aesthetic medicine. While a lot has changed in healthcare, one
thing has not: Ethicon remains committed to developing the best surgical
solutions to help doctors heal both the wounds you can see and the ones
Caring for the world, one person at a time … inspires and unites the
people of Johnson & Johnson. We embrace research and science - bringing
innovative ideas, products and services to advance the health and well-
being of people. Our 119,400 employees at more than 250 Johnson &
Johnson companies work with partners in healthcare to touch the lives of
over a billion people every day, throughout the world.
S u t u r e M an u f ac t u r i n g P lan t s i n
I n d i a
Baddi
Aurangabad
G r o w t h & E x p an s i o n O f
Johnson & Johnson
Since our founding in 1886, we have grown to meet the health care
needs of people worldwide. Through mergers, acquisitions and the
formation of new companies, we have become the world ’s largest and
most broadly based health care company. Here are some highlights of
our historical growth.
In 1886, our founders – Robert Wood Johnson, James Wood Johnson and
Edward Mead Johnson – started a small medical products company in
New Brunswick, New Jersey. They made the first-ever commercial
sterile surgical dressings, which helped save the lives of patients.
We introduced dental floss, the first Aid kits, sanitary napkins for
women, sterile sutures, JOHNSON ’S Baby Powder, and BAND-AID
Brand Adhesive Bandages.
Our international expansion began with Canada in 1919 and
England in 1924.
Our disaster relief program began in 1906 when, within hours of
the San Francisco earthquake and fire, we sent trainloads of our
products to the city to help survivors.
1926 – 1 94 6: G r o w t h o f P r o d u c t L i n e s a n d E x p a n s i o n
O v er s eas H e lp J o h n s o n & J o h n s o n G o P u b l ic
In 1943 our chairman Robert Wood Johnson wrote Our Credo, outlining
our responsibilities to doctors, nurses, patients, consumers,
employees, and the community. During this period we also continued
our overseas growth and began to broaden our efforts in
pharmaceuticals and medical products.
We expanded into Mexico, South Africa, Australia, France,
Belgium, Ireland, Switzerland, Argentina, and Brazil.
We introduced MODESS sanitary napkins and JOHNSON ’S Baby Oil
and Baby Lotion. We also launched the first U.S. prescription birth
control product, ORTHO GYNOL Gel, in 1931.
In 1944 we became a publicly traded company.
1946 – 1 96 6: C o n t i n u e d P r o d u c t G r o w t h a n d O u r C r ed o
P o s it i o n J o h n s o n & J o h n s o n as R e s p o n s i b l e In d u s t r y
L e a d e r .
1966 – 1 98 6: M e d i c a l A d v a n c e s C r ea t e G r o u n d b r e a k i n g
P r o d u c t s
newborns.
HALDOL (haloperidol),
the gold standard for treating
schizophrenia for over 25 years.
MONISTAT (miconazole nitrate) Cream, a milestone product for
women’s health.
VICRYL Synthetic absorbable sutures, an important new tool for
surgeons.
The PROXIMATE Linear Stapler, a new way to close
1986 – 2 00 8: In d u s t r y L e ad e r s h i p E n h a n c e d b y A c q u i s i t io n s
a n d I n t e r n a l D e v el o p m e n t
L o o k i n g t o t h e F u tu r e
2. Accounts departments
3. Purchase departments
4. Store department
6. IT department
7. R&D Department
RESEARCH METHODOGY
Research methodology is the way to systematically solve
the research problem. Objective of research study is Analysis of
inventory of Johnson & Johnson Ltd. Analyzing of inventory, we
determining following inventories-1. Raw materials inventory.
4. Supplies inventory.
INTRODUCTION:
MEANING OF INVENTORY:-
NATURE OF INVENTORIES:-
RAW MATERIALS:-
WORK IN PROGRESS:-
FINISHED GOODS:-
SUPPLIES:
OBJECTIVES OF INVENTORY
MANAGEMENT
B. Financial Objectives:
TYPES OF INVENTORY
S upplies
Demand
Inventory in
Hand place
Orders
Purchase
dep‘t.
Inventory cycle
inventory stocks when a strike is on the anvil, are all examples of
anticipation inventories.
CONTROL OF MATERIALS:
Rigid control over materials are necessary not only to guard against theft,
but also to minimize waste and misuse from causes such as excessive
inventories, over issue, deterioration, spoilage, and obsolescence. There are
certain prerequisites to an effective control system for materials:
IMPORTANCE OF INVENTORY
CONTROL:
(c) Carrying Cost: This includes the expenses for storing and
handling the goods. It comprises storage costs, insurance costs,
spoilage costs, cost of funds tied up in inventories etc.
ESSENTIAL OF INVENTORY
CONTROL SYSTEM
For an efficient and successful inventory control there are
certain important conditions that are as follows:
(1) Classification and Identification of inventories: The
usual inventory of manufacturing firm includes raw-
material, stores, work-in-progress and component etc. To
facilitate prompt recording the dealing, each item of the
inventory must be assigned a particular code number and it
must be classified in suitable group or sub-divisions. ABC
analysis of material is very helpful in this context.
(2) Standardization and simplification of inventories:
In order to facilitate inventory control, the inventory line should
be simplified. It refers to the elimination of excess types and
sizes of items. Simplification leads to reduction in classification
of inventories and its carrying costs. Standardization, on the
other hand, refers to the fixation of standards of raw material to
be purchased and specification of the components and tools to
be used.
T E C H N IQ U E S O F IN V E N T O R Y
CONTROL
(a) Lead time i.e. time lag between intending and receiving the
material.
But if normal usage and normal lead time is not known then
average usage will be treated as normal usage and average re-
order will be treated as normal re-order period.
(a) Rate of material usage: Generally this rate is found out as
usage rate per day, pre week or per month. The quantity of
production fluctuates according to demand of the product which
results in variation in usage rate.
(b) Ordering Period: The time taken in preparing the order for
purchase of material is called ordering period. In some concerns
this period may be significant but in large concerns this period is
significant because before placing the order the purchase
manager has to trace out the best suppliers, after that only he
places the order.
Situation2:
When rate of usage is known with certainty and lead time is also
known but is variable:
Situation4:
When the rate of usage and lead time are known and are
variable;
Danger Level
ECONOMICORDERQUANTITY
TECHNIQUE
Ordering costs increase with the number of order; thus the more
frequently inventory is acquired, the higher the firm‘s ordering
costs. Ordering costs decrease with increasing size of inventory.
Carrying costs vary with inventory size. The economic size of
inventory would thus depend on trade-off between carrying costs
and ordering costs.
1200
1000
800
Q/2
600
Stock 400
200
50
0 2 4 6 8 10 15
Time
Order size
TOC = AO/ Q
2 2
TCC =Qc
2
TC = Qc + AO
2 Q
Equation (4) reveals that for a large order quantity, Q, the carrying
cost will increase, but the ordering costs will decrease. On the
other hand, the carrying costs will be lower and ordering cost will
be higher with the order quantity. Thus, the total cost function
represents a trade-off between the carrying costs and ordering
costs for determining the EOQ.
Carrying cost
EOQ = 2AO
C
Graphic approach:
Minimum total
Cos t
Carrying cost
Reorder Point:
the reorder point. The reorder point is that inventory level at
which an order should be placed to replenish the inventory. To
determine the reorder point under certainty, we should known: (a)
lead time (b) average usage, and (c) economic order quantity.
Lead time is the normally taken is replenishing inventory after
the order has been placed. By certainty we mean that usage and
lead time do not fluctuate. Under such a situation, reorder point is
simply that inventory level which will be maintained for
consumption during the lead time. That is:
Safety stock:
The carrying costs are the costs associated with the maintenance
of inventory. Since the firm is required to maintain additional
inventory, in excess of the normal usage, additional carrying costs
are involved.
Max. Inventory
Average usage
EOQ
Avg. inventory----------------------------------------------------
Re-order point-----------------------------------------------------
max.usage
spares may be avoided at times. If the lead time of these spares is
less, then stocking of these spares can be avoided.
EOQ and Total Inventory Cost: At EOQ level total inventory
cost is minimum. Total inventory cost is the sum of material
purchase cost, ordering cost and carrying cost
The ‗B‘ group will consist of the items accounting for the next
largest investment.
The ‗C‘ items can receive the minimum attention: they will
probably be ordered in large quantities in order to obtain them
at the lowest price.
Just-in-time(JIT)System:
Japanese firms popularized the just-
in-time (JIT) system in the world. In a JIT system material or the
Materials inventory-opening
+ Purchases
the levels are too high there might be a perfectly good reason
why the level of Inventory is being maintained. The ratios also
indicate the situation and trend. However, the limitation of
ratios should be kept in mind. They are not an end themselves,
but only tools of sound Inventory Management.
VALUATION OF INVENTORIES
OBJECTIVE:
DEFINITIONS
3. Cost of Inventories
The cost of inventories should comprise all costs of purchase,
costs of conversion and other costs incurred in bringing the
inventories to their present location and condition.
4. Costs of Purchase
The costs of purchase consist of the purchase price including
duties and taxes (other than those subsequently recoverable by
the enterprise from the taxing authorities), freight, inwards and
other expenditure directly attributable to the acquisition. Trade
discounts, rebates, duty drawbacks and other similar items are
deducted in determining the costs of purchase.
5. Costs of Conversion
The costs of conversion of inventories include costs
directly related to the units of production, such as direct
labour. They also include a systematic allocation of fixed and
variable production overheads that are incurred in converting
materials into finished goods. Fixed production overheads are
those indirect costs of production that remain relatively
constant regardless of the volume of production, such as
depreciation and maintenance of factory buildings and the cost
of factory management and administration. Variable production
overheads are those indirect costs of production that vary
and condition and are, therefore, usually not included in the cost
of inventories.
13. The cost of inventories, other than those dealt with in
paragraph 11, should be assigned by using the first-in, first-out
(FIFO), or weighted average cost formula. The formula used
should reflect the fairest possible approximation to the cost
incurred in bringing the items of inventory to their present
location and condition.
16. The retail method is often used in the retail trade for
measuring inventories of large numbers of rapidly changing
items that have similar margins and for which is impracticable
to use other costing methods. The cost of the inventory is
determined by reducing from the sales value of the inventory
the appropriate percentage gross margin. The percentage used
takes into consideration inventory which has been marked down
to below its original selling price. An average percentage for
each retail department is often used.
18. Inventories are usually written down to net realizable value on
an item-by-item basis. In some circumstances, however, it may
be appropriate to group similar or related items. This may be
the case with items of inventory relating to the same product
line that have similar purposes or end uses and are produced
and marketed in the same geographical area and cannot be
practicably evaluated separately from other items in that
product line. It is not appropriate to write down inventories
based on a classification of inventory, for example, finished
goods, or all the inventories in a particular business segment.
20. Estimates or net realizable value also take into consideration the
purpose for which the inventory is held. For example, the net
22. Disclosure.
DATA COLLECTION
In analysis of inventory of J&J, We collect the data by the
different sources. We collect the primary and secondary data.
SECONDARY DATA – The secondary data are those data the
already in presence for specific purpose we use the secondary
) Includes reserve for customer rebates of $729 million, $721 million, $710
(1
4.5% over the prior year. International sales were $12.6 billion, a decrease
of 0.2%, with growth of 4.0% from operations and a decrease of 4.2%
resulting from the negative impact of currency fluctuations. The DePuy
franchise achieved sales of $5.4 billion in 2009, a 4.6% increase over the
prior year. This was primarily due to growth in the spine, hip and knee
product lines. Additionally, new product launches in the Mitek sports
medicine product line contributed to the growth.
The Ethicon Endo-Surgery franchise achieved sales of $4.5 billion in 2009, a
4.8% increase over the prior year. This was attributable to growth in the
endoscopy, HARMONIC ® , ENSEAL ® and Advanced Sterilization product
lines. The Ethicon franchise achieved sales of $4.1 billion in 2009, a 7.3%
increase over the prior year. This was attributable to growth in the sutures,
biosurgical and mesh product lines in addition to sales of newly acquired
products from the acquisitions of Omrix Biopharmaceuticals, Inc. and
Mentor Corporation. The growth was partially offset by the divestiture of the
Professional Wound Care business of Ethicon, Inc. in the fiscal fourth quarter
of 2008.
Sales in the Cordis franchise were $2.7 billion, a decline of 10.3% versus the
prior year. The decline reflects lower sales of the CYPHER ® Sirolimus-
eluting Coronary Stent due to increased global competition. The decline was
partially offset by growth of the Biosense Webster business. The Vision Care
franchise achieved sales of $2.5 billion in 2009, a 0.2% increase over prior
year primarily related to growth in the Astigmatic contact lens product line
offset by the negative impact of currency. Sales in the Diabetes Care
franchise were $2.4 billion in 2009, a decline of 3.7% versus the prior year.
Declines in the LifeScan product line were partially offset by growth of the
Animas insulin delivery business resulting from new product launches and
continued development in international markets. The Ortho-Clinical
Diagnostics franchise achieved sales of $2.0 billion in 2009, a 6.6% increase
over the prior year primarily attributable to the recent launch of the VITROS
® 3600 and 5600 analyzers.
The Medical Devices and Diagnostics segment achieved sales of $23.1
billion in 2008, representing an increase of 6.4% over the prior year, with
operational growth of 3.5% and 2.9% due to a positive impact from currency
fluctuations. U.S. sales were $10.5 billion, an increase of 1.0%. International
sales were $12.6 billion, an increase of 11.3%, with 5.8% from operations
and a positive currency impact of 5.5%. Analysis of Consolidated Earnings
Before Provision for Taxes on Income Consolidated earnings before
provision for taxes on income decreased by $1.1 billion to $15.8 billion in
2009 as compared to the $16.9 billion earned in 2008, a decrease of 6.9%.
The decrease was primarily related to lower sales, the negative impact of
product mix, lower interest income due to lower rates of interest earned and
restructuring charges of $1.2 billion. This was partially offset by lower
Operatlll'lig Profit.
by Segment.
( n b. lll()t'rj. of ooll.:us.)
•
•
C:.tn""'"'cr
Ph....-""'"'-"t!ulic_,.
loJiedK:< I Uevices
ar- Cl ...;·.a:gros.t..c.s.
PHARMACEUTICAL SEGMENT
(tJ Inc ludes reseJVe for customer rebates of $372 million at January 3, 2010 and $344 million at December 28 , 2008, recorded as
a contra asset.
2
< ! Includes $115 million adj ustment related to previously estimated accr ued sales reserves.
AIJanuary 3. 2010 andDecember 28,2008 (Dollars 11Millions Excep1Share and Per Shar e Data){Note 1) 2009 2008
Asse ts
Currentassets
Cash and cash equivalents (Notes 1and 2) $15,810 10,768
Marketable securities (Notes 1and 2) 3,615 2,041
Accounts r eceivable tr ade,less allowances f or doubtfulaccounts $333 (2008, $268) 9,646 9,719
Inventor ies (Notes 1and 3) 5,180 5,052
Def er re dtaxesonincome(Note 8) 2,793 3,430
Pr epaid expenses and other r eceivables 2 497 3.367
Current liabilities
Loans and notes payable (Note 7) s 6,318 3,732
Accounts payable 5,541 7,503
Accr uedliabil ies 5,796 5,531
Accrued r ebates, r eturns and promotions 2,028 2,237
Accrued salar ies,wages and commissions 1,606 1,432
Accrued taxes on income 442 417
Shareholder s' e uit
Pr eferred stock -without par value
(authoriZed and unissued 2,000,000 shares)
Common stock -par value $1.00 pershare(Note 12)
(authoriZed 4,320,000,000 shares; issued 3,119,843,000 shar es) 3,120 3,120
Accumulatedothercompr ehensive income (Note 13) (3,058) (4,955)
Retained earnings 70 306 63.379
70,368 61,544
Less:commonstock held in tr easury,at cost (Note 12)
(365,522,000 shar es and 350,665,000 shar es) 19,780 19,033
(Dollars in Millions Except Per Share Figures) (Note 1) 2009 2008 2007
Basic average shares outstanding (Notes 1and 15) 2,759.5 2,802.5 2,882.9
Diluted average shares outstanding (Notes 1 and 15) 2,789.1 2,835.6 2,910.7
Normally each fiscal year consists of 52 weeks, but every five or six years
the fiscal year consists of 53 weeks, as was the case in
2009 and will be the case again in 2014.
RECLASSIFICATION
Certain prior period amounts have been reclassified to conform to current
year presentation.
2. Cash, Cash Equivalents and Current Marketable Securities
As of January 3, 2010, current marketable securities consist of $3,434
million and $181 million of government securities and obligations and
corporate debt securities, respectively.
As of December 28, 2008, current marketable securities consist of $1,663
million, $342 million and $36 million of government securities and
obligations, corporate debt securities and time deposits, respectively.
Fair value of government securities and obligations and corporate debt
securities were estimated using quoted broker prices in active markets.
The Company invests its excess cash in both deposits with major banks
throughout the world and other high-quality money market instruments. The
Company has a policy of making investments only with commercial
institutions that have at least an A (or equivalent) credit rating.
3. Inventories
At the end of 2009 and 2008, inventories were comprised of:
4. Property, Plant and Equipment
At the end of 2009 and 2008, property, plant and equipment at cost and
accumulated depreciation were:
The Company capitalizes interest expense as part of the cost of construction
of facilities and equipment. Interest expense capitalized in 2009, 2008 and
2007 was $101 million, $147 million and $130 million, respectively.
Depreciation expense, including the amortization of capitalized interest in
2009, 2008 and 2007, was $2.1 billion, $2.0 billion
January 3, 2010 December 28, 2008
Amortized Unrealized Estimated Amortized Unrealized Estimated
(Dollars in Millions) Cost Gains/(Losses) Fair Value Cost Gains/
(Losses) Fair Value
Current Investments
Cash $ 2,517 — 2,517 3,276 — 3,276
Government securities and obligations 13,370 1 13,371 7,486 4 7,490
Corporate debt securities 426 — 426 627 1 628
Money market funds 1,890 — 1,890 813 — 813
Time deposits 1,222 — 1,222 607 — 607
Total cash, cash equivalents and current marketable securities $ 19,425 1
19,426 12,809 5 12,814
Total sales
Inventory turn over ratio = Average inventory
The sale of J&J in year 2007 is 720 million & its investment
on inventory is 126 million.
0
Feb
10 40 2.1 840 60 - 129
00 0 0 00 20
16 2 2.4 482 80 - 177
0 1 0 00 40
0
0
March
3 2 2.4 482 10 - 225
0 1 0 00 60
0 0
0
17 40 2.1 840 60 - 141
00 0 0 00 60
29 4 2.2 916 10 - 233
0 9 0 00 20
0 0
0
Apr
4 2 2.1 428 12 - 276
0 4 0 00 00
0 0
0
18 40 @ 934 60 - 182
00 0 00 60
0
23 2 2.0 408 10 - 223
0 4 0 00 40
0 0
0
May
Interpretation -
Q R A Q R A Q A
300 9 2700 0
Interpretation:-
The value of inventory under periodic & perpetual inventory system is
different. The value of inventory under perpetual system is more than
periodic system
Re-order period
= 267 units
= 706 units
Interpretationofresult : -
1. After calculation the re-order level of J&J is 975 units but the actual re-
order quantity is 878 units.
2. The minimum stock level of J&J is 267 units.
3. The maximum stock level of J&J is 1028 units.
4. The average stock level must be 706 units.
500 0 0 0 0 0
Expected stock out cost == stock out cost * probability of stock out .
PROBLEMS AND
SUGGESTIONS
PROBLEMS FACED BY THE ORGANITION
SUGGESTIONSTOTHEORGANISATION:
4. Store manager give the proper knowledge about engineering & raw
materials.
CONCLUSION
The goal of the wealth maximization is affected by the efficiency with
which inventory is managed. Inventories constitute about 60% of
current assets of companies in India. The manufacturing companies
hold inventories in the form of raw materials, work in progress and
finished goods. Inventories facilitate smooth production and sales
operation (transaction motive), to guard against the risk of
Respondents):-
qualifications
administrative posts.
DATA ANALYSIS
of the study.
management system?
80%
70%
60%
50%
40% Yes
30% No
10%
0%
Yes 72%
No 20%
Do not know/Can Not say 8%
cent+08 per cent of the respondents who are either not aware or
company?
cent
cent
per cent
cent
cent
Interpretatio
n:
evolved?
Interpretatio
n:
which it was in place. This is evident from the 67 per cent of the
per cent
cent
cent
cent
cent
Interpretatio
n:
inventory management?
50%
45%
40%
35%
30%
25% Yes
20% No
15%
Do not know/Can Not
10%
5%
0%
Yes 48%
No 30%
Do not know/Can Not say 22%
Interpretatio
n:
inventory?
35%
30%
25%
20%
Skilled and trained
15%
Only skill ed but not
10%
trained
Interpretation:
management?
Interpretation:
details management.
Interpretation:
needs.
cent
per cent
cent
cent
Interpretatio
n:
your company?
per cent
per cent
cent
cent
Interpretation:
ANNEXURER
QUESTIONNAIRE
system?
management system?
It has made storage and retrieval of material easier --------- 37 per cent
management?
inventory?
management?
10. Do you think that the software used by your company is
11. What is the prime challenge before yor company with rehard to
inventory management?
company?
Bibliography
Advanced Accountancy
Ninth Edition
S N Maheshwari, S K Maheshwari
Financial Management
Ninth Edition
I M Pandey
Management Accounting
Third Edition
M Y Khan, P K Jain
Company
Johnson & Johnson Ltd.